“Rethink and redesign and rebuild an engine that allows you to go from an idea right through to a candidate that is going into clinical development.”
Carl Hansen, AbCellera CEO sits down with Fierce Biotech’s Rebecca Willumson at the JPM Healthcare Conference 2023 to talk about how AbCellera is rethinking, redesigning and rebuilding an antibody engine that allows you to go from target to clinical candidate.